Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer

Cancer Medicine
Tadaaki YamadaKoichi Takayama

Abstract

Treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR-mutated non-small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations who exhibit clinical outcomes that require treatment with immune checkpoint inhibitors (ICIs). Therefore, to identify eligible cases to treat with ICIs, we retrospectively analyzed the correlation between clinical features and the efficacy of ICIs in patients with EGFR mutations. We retrospectively analyzed patients with advanced NSCLC harboring EGFR mutations who were treated with ICIs after developing resistance to EGFR-TKIs between February 2016 and April 2018 at 6 institutions in Japan. The association between clinical outcomes and the efficacy of ICIs was investigated. We enrolled 27 patients who harbored EGFR-activating mutations. The objective response and disease control rates were higher in patients with uncommon EGFR mutations than in those with common EGFR mutations (71% vs 35.7% and 57% vs 7%, P = 0.14 and P < 0.01, respectively). Patients with uncommon EGFR mutations or without T790M mutations exhibited a significantly longer median progress...Continue Reading

References

Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Mar 25, 2011·Science Translational Medicine·Lecia V SequistJeffrey A Engelman
Sep 19, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jul 11, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K AzumaI Okamoto
Aug 19, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M RiihimäkiK Hemminki
Dec 4, 2014·Molecular and Clinical Oncology·Tomohiro TamuraNobuyuki Hizawa
Feb 7, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nan ChenLi Zhang
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Mar 6, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Takehito Shukuya, David P Carbone
May 27, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Justin F GainorMari Mino-Kenudson
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 22, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chee Khoon LeeJames Chih-Hsin Yang
Jan 21, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Deepa RangachariDaniel B Costa
Nov 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H YoshidaT Hirai
Nov 28, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hai-Yan TuYi-Long Wu
Jan 2, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ross A SooByoung Chul Cho
Mar 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerJulie Brahmer
Mar 25, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yasuto YoneshimaIsamu Okamoto

❮ Previous
Next ❯

Citations

May 16, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K HastingsK Politi
Jul 11, 2020·Cancer Immunology, Immunotherapy : CII·Eiki IchiharaKatsuyuki Kiura
Sep 29, 2020·Immunotherapy·Fangfang LiuQian Chu
Jan 20, 2021·Nature Reviews. Cancer·Shogo KumagaiHiroyoshi Nishikawa
Sep 29, 2019·Seminars in Cancer Biology·Peter T HarrisonPaul H Huang
Jan 14, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James Chih-Hsin YangEdward S Kim
Jun 12, 2021·Frontiers in Oncology·Kenneth K W ToWilliam C S Cho
Jul 3, 2021·International Journal of Molecular Sciences·Edouard DantoingFlorian Guisier

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

Prism
GraphPad
RECIST

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.